NCT03162627 - Selumetinib and Olaparib in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2017

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions

Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Male Genital OrgansMalignant Neoplasms of Thyroid and Other Endocrine Glands

Interventions

DRUG

Selumetinib

"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."

DRUG

Olaparib

"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston